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Abstract
Objective:	To	examine	the	association	between	the	use	of	invasive	treatments	for	post-
partum	hemorrhage	and	the	risk	of	sepsis	and	severe	sepsis.
Methods:	Secondary	data	analysis	of	the	WOMAN	randomized	controlled	trial,	includ-
ing	20	060	women	with	postpartum	hemorrhage	 in	21	countries.	Logistic	 regression	
with	random	effects	was	used.
Results:	 The	 cumulative	 incidence	 was	 1.8%	 for	 sepsis	 and	 0.5%	 for	 severe	 sepsis.	
All-	cause	mortality	was	40.4%	 in	women	with	 severe	sepsis	versus	2.2%	 for	women	
without.	After	adjusting	for	bleeding	severity	and	other	confounders,	intrauterine	tam-
ponade,	hysterectomy,	and	laparotomy	increased	the	risk	of	sepsis	(aOR	1.77	[95%	CI	
1.21–2.59],	P=0.004;	aOR	1.97	[95%	CI	1.49–2.65],	P<0.001;	and	aOR	6.63	[95%	CI	
4.29–10.24],	P<0.001,	respectively)	and	severe	sepsis	(aOR	2.60	[95%	CI	1.47–4.59],	
P=0.002;	aOR	1.97	[95%	CI	0.83–2.46],	P=0.033;	and	aOR	5.35	[95%	CI	2.61–10.98],	
P<0.001,	respectively).
Conclusion:	In	this	secondary	data	analysis,	certain	invasive	treatments	for	postpartum	
hemorrhage	appear	to	increase	the	risk	of	sepsis.	Further	research	is	needed	to	confirm	
this	finding	and	investigate	the	role	of	prophylactic	antibiotics	during	these	procedures.	
The	harms	and	benefits	of	such	interventions	must	be	carefully	weighed,	both	in	treat-
ment	guidelines	and	during	individual	patient	management.
Trial Registration: ISRCTN76912190	
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1  | INTRODUCTION
Every	 day,	 approximately	 830	women	 die	worldwide	 as	 a	 result	 of	
pregnancy	and	childbirth.1	Most	maternal	deaths	(99%)	occur	in	low-	
and	middle-	income	countries	(LMICs),1	and	are	caused	by	hemorrhage	
(27%),	 hypertensive	 disorders	 (14%),	 or	 sepsis	 (10.7%).2	 Classifying	
death	 by	 a	 single	 primary	 cause,	 however,	 misses	 the	 potentially	
important	contribution	of	other	morbidities	and	their	interactions.
Imprecise	 and	 varying	 definitions	 of	 maternal	 sepsis	 have	 been	
used	for	many	years.	In	2017,	WHO	responded	by	proposing	a	defi-
nition	of	maternal	 sepsis	 as	 a	 “life-	threatening	 condition	defined	 as	
organ	 dysfunction	 resulting	 from	 infection	 during	 pregnancy,	 child-
birth,	post-	abortion,	or	postpartum	period”.3	This	change	is	in	line	with	
the	new	Sepsis-	3	definition	for	the	general	population.4	Specific	crite-
ria	for	identification	are	yet	to	be	developed.3
Risk	factors	for	peripartum	infections	include	pre-	existing	mater-
nal	 conditions	 (obesity,	 diabetes,	 malnutrition,	 severe	 anemia)	 and	
factors	related	to	childbirth	 (cesarean	delivery,	prolonged	rupture	of	
membranes,	 multiple	 vaginal	 examinations,	 placental	 retention).5–7 
Interest	in	postpartum	hemorrhage	(PPH)	as	a	risk	factor	for	sepsis	has	
recently	 been	 sparked	 by	 an	 association	 found	 in	 population-	based	
studies	in	high-	income	countries.8–11	It	is	possible	that	invasive	treat-
ments	 for	 PPH,	 such	 as	 intrauterine	 tamponade	 and	 hysterectomy,	
could	 increase	 the	 risk	of	 infection	by	 introducing	 (vaginal)	 bacteria	
into	the	uterus	and	abdomen.
Despite	 the	 possible	 infectious	 risk,	 antibiotic	 prophylaxis	 is	
rarely	and	inconsistently	mentioned	in	PPH	treatment	guidelines;	the	
American	College	of	Obstetricians	and	Gynecologists	12	and	the	Royal	
College	 of	Obstetricians	 and	Gynaecologists	 in	 the	 UK	 13	 make	 no	
mention	 at	 all.	WHO	guidelines	 only	 recommend	prophylactic	 anti-
biotics	for	manual	removal	of	the	placenta.14	This	difference	in	guide-
lines	indicates	a	lack	of	evidence	in	the	area.
The	 World	 Maternal	 Antifibrinolytic	 (WOMAN)	 trial	 recruited	
women	with	PPH	 in	21	 countries.15	Tranexamic	 acid	was	 shown	 to	
reduce	mortality	from	hemorrhage	by	19%.	Sepsis	was	noted	to	be	an	
important	complication.	The	aim	of	the	present	study	was	to	examine	
this	large	dataset	to	determine	the	association	between	invasive	treat-
ment	for	PPH	and	sepsis.
2  | MATERIALS AND METHODS
We	 conducted	 a	 secondary	 analysis	 of	 all	 women	 recruited	 to	 the	
WOMAN	trial	to	assess	the	association	between	invasive	treatment	
for	PPH	and	sepsis.	Our	primary	outcome	was	sepsis,	defined	by	the	
study	authors	at	the	onset	of	the	trial.	Our	secondary	outcome	was	
sepsis	with	organ	dysfunction.	Main	exposures	were	manual	removal	
of	placenta,	hysterectomy,	brace	sutures,	artery	ligation	(individually	
or	 a	 combination	of	 the	 uterine	 artery,	 ovarian	 artery,	 internal	 iliac	
artery),	intrauterine	tamponade,	and	“laparotomy	for	other	reasons.”
The	 WOMAN	 trial	 is	 a	 randomized,	 double-	blind,	 placebo-	
controlled	trial	to	evaluate	the	effect	of	tranexamic	acid	on	mortality	
or	 hysterectomy	 in	women	with	 PPH.	 Details	 have	 been	 described	
elsewhere.15	In	brief,	20	060	women	were	recruited	in	193	facilities	in	
21	countries.	Women	over	16	years	were	eligible	if	they	had	a	clinical	
diagnosis	of	PPH	(estimated	blood	loss	>500	mL	after	vaginal	delivery	
or	>1000	mL	after	cesarean,	or	any	blood	 loss	sufficient	to	compro-
mise	hemodynamic	stability).	Baseline	characteristics	included	mater-
nal	age,	place	and	type	of	delivery,	complete	expulsion	of	the	placenta,	
primary	 cause	 of	 bleeding,	 and	 use	 of	 uterotonics.	 Hemodynamic	
instability	at	entry	was	based	on	clinical	signs	(e.g.	low	blood	pressure,	
tachycardia,	 falling	urine	output).	The	primary	outcome	was	 a	 com-
posite	of	death	from	all	causes	or	hysterectomy.	Secondary	outcomes	
included	complications	(renal	failure,	cardiac	failure,	respiratory	failure,	
hepatic	failure,	sepsis,	and	seizures)	and	surgical	interventions	to	treat	
hemorrhage	 (intrauterine	 tamponade,	 embolization,	 brace	 sutures,	
arterial	 ligation,	hysterectomy,	and	 laparotomies	done	for	other	rea-
sons).	Outcomes	were	recorded	from	medical	records	at	time	of	death,	
at	discharge,	or	42	days	postpartum,	whichever	occurred	first.
Sepsis	in	the	WOMAN	trial	was	defined	as	infection	plus	systemic	
inflammatory	 response,	 in	 line	with	 the	 previous	 adult	 definition	 of	
sepsis	 that	was	 still	 in	 use	when	 inclusion	 started	 in	 2010.16	 In	 the	
present	analysis,	a	new	variable	“severe	sepsis”	was	created	as	sepsis	
plus	organ	dysfunction.	Note	that	this	“severe	sepsis”	variable	equals	
the	term	sepsis	as	defined	by	the	2016	Sepsis-	3	consort.4	Organ	dys-
function	in	the	WOMAN	trial	was	diagnosed	as	follows:	renal	failure	
required	either	a	rise	 in	serum	creatinine	of	greater	than	or	equal	to	
26 μmol/L	 (0.29	mg/dL)	within	48	hours,	 rise	 in	serum	creatinine	of	
50%	or	greater	known	or	presumed	to	have	occurred	within	the	past	
7	days,	urine	output	less	than	0.5	mL/kg/h	for	more	than	six	consec-
utive	hours,	or	(in	those	with	pre-	existing	renal	disease)	a	serum	cre-
atinine	 rise	of	200%	or	more	 from	 index	 serum	creatinine	or	 serum	
creatinine	increased	to	350	μmol/L	(4	mg/dL).	Cardiac	failure	required	
the	 presence	 of	 typical	 signs	 or	 symptoms	 (e.g.	 orthopnea,	 hepato-
jugular	reflux)	or	a	reduced	left	ventricular	ejection	fraction,	relevant	
structural	 heart	 disease,	 or	 diastolic	 dysfunction.	 Respiratory	 failure	
required	 a	partial	 pressure	of	oxygen	 less	 than	60	mm	Hg	 (8.0	 kPa)	
on	 room	air,	 sea	 level.	Hepatic	 failure	 required	deterioration	 in	 liver	
function	with	 changes	 in	mental	 status	 and	 coagulopathy.	No	other	
types	of	organ	dysfunction	were	recorded	(Table	S1	holds	“guidance	
on	diagnosing	complications”).
Percentages	 and	medians	were	 used	 to	 describe	 the	 data.	 Risk	
factors	 for	 sepsis	were	examined	using	 logistic	 regression	with	 ran-
dom	effects	to	account	for	clustering	by	facility.	Main	exposures	were	
manual	removal	of	placenta,	hysterectomy,	brace	sutures,	artery	liga-
tion	(individually	or	a	combination	of	the	uterine	artery,	ovarian	artery,	
internal	 iliac	 artery),	 intrauterine	 tamponade,	 and	 “laparotomy	 for	
other	reasons.”	We	built	a	comprehensive	model	including	all	possible	
confounders	(age,	type	of	delivery,	hospital	delivery,	primary	cause	of	
hemorrhage,	and	markers	of	bleeding	severity:	estimated	blood	loss,	
systolic	 blood	 pressure,	 and	 hemodynamic	 instability).	 New	 organ	
dysfunctions	are	thought	to	result	from	sepsis	rather	than	preceding	
it	and	were	therefore	excluded	as	risk	factors.	The	same	model	was	
rerun	with	severe	sepsis	as	the	outcome.
Comprehensive	 logistic	 regression	 models	 with	 random	 effects	
were	 also	 used	 to	 assess	 the	 effect	 of	 (severe)	 sepsis	 on	 all-	cause	
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mortality.	A	 priori	 confounders	were	 age,	 type	 of	 delivery,	 signs	 of	
hemodynamic	instability,	place	of	delivery,	prophylactic	use	of	utero-
tonics,	and	primary	cause	of	hemorrhage.	Organ	dysfunction	 lies	on	
the	causal	pathway	and	was	excluded.
All	 analyses	were	 carried	out	 using	 Stata	version	14	 (StataCorp,	
College	Station,	TX,	USA).	Odds	ratios,	95%	confidence	intervals,	and	
P	values	from	likelihood	ratio	tests	are	presented.	We	considered	a	P 
value	of	<0.05	to	be	significant.
The	initial	study	was	registered	under	ISRCTN76912190.	Approval	
was	obtained	from	local	ethics	committees	and	the	ethics	committee	
of	 the	 London	 School	 of	 Hygiene	 and	 Tropical	 Medicine	 (LSTHM).	
Ethical	approval	for	secondary	data	analysis	was	granted	by	the	eth-
ics	 committee	 of	 LSTHM	 under	 ref	 number	 13400.	 The	WOMAN	
trial	obtained	consent	from	its	participants	in	line	with	the	procedure	
described	in	the	protocol.	No	additional	patient	information	was	col-
lected	for	the	present	study.
3  | RESULTS
A	total	of	20	060	women	with	PPH	were	 included	 in	 the	WOMAN	
trial,	with	a	mean	age	of	28	years.	Data	on	sepsis	were	available	for	
20	 018	 (42	 missing,	 0.2%).	 During	 the	 period	 of	 observation,	 483	
women	died	(all-	cause	mortality	2.4%).	There	were	365	cases	of	sepsis	
reported	(1.8%),	of	which	104	met	our	criteria	for	severe	sepsis	(0.5%	
of	the	total	population).	Most	women	delivered	in	hospital	(87.9%)	and	
almost	all	received	prophylactic	uterotonics	(96.2%).	Almost	one-	third	
(29.1%)	 of	women	were	 delivered	 by	 cesarean.	Data	 collection	was	
nearly	complete	for	most	variables.	Table	1	presents	an	overview	of	
the	population	characteristics	and	missing	values.
In	univariate	analysis,	all	surgical	interventions	to	treat	PPH	showed	
evidence	of	an	association	with	sepsis	(Table	1).	Sepsis	occurred	more	
than	twice	as	often	in	women	who	underwent	cesarean	delivery	(OR	
2.51;	95%	CI,	2.00–3.16;	P<0.001).	A	higher	proportion	of	hemody-
namically	unstable	women	developed	sepsis.
After	adjusting	 for	bleeding	 severity	and	other	confounding	 fac-
tors,	brace	sutures,	manual	placenta	removal,	and	artery	ligation	were	
no	longer	associated	with	sepsis.	Strong	evidence	(P<0.001)	remained	
for	associations	between	sepsis	and	hysterectomy	(aOR	1.97;	95%	CI,	
1.49–2.65)	and	laparotomy	(aOR	6.63;	95%	CI,	4.29–10.24),	but	effect	
sizes	were	smaller	than	in	univariate	analysis.	The	estimated	effect	of	
intrauterine	 tamponade	 (aOR	 1.77;	 95%	 CI,	 1.21–2.59])	 remained	
essentially	unchanged	(P=0.004).
The	model	for	severe	sepsis	adjusted	for	the	same	confounders	as	
above,	 including	bleeding	severity,	but	contained	 fewer	events	 (104	
cases	 of	 severe	 sepsis).	The	 confidence	 intervals	 are	wider,	 but	 the	
main	 results	 remain	 similar.	 The	 risk	 factors	 associated	with	 severe	
sepsis	were	hysterectomy	(aOR	1.97;	0.83–2.46;	P=0.033),	intrauter-
ine	tamponade	(aOR	2.60;	95%	CI,	1.47–4.59;	P=0.002),	laparotomy	
(aOR	 5.35;	 95%	CI,	 2.61–10.98;	P<0.001),	 and	 artery	 ligation	 (aOR	
2.50;	1.28–4.89;	P=0.010)	(Table	2).
A	diagnosis	of	sepsis	was	a	strong	predictor	 for	mortality	 in	 this	
population	 (P<0.001).	Forty-	two	women	out	of	the	104	with	severe	
sepsis	died	(40.4%),	compared	with	13	deaths	out	of	261	women	with	
nonsevere	sepsis	(5.0%)	and	428	deaths	out	of	19	653	women	without	
sepsis	(2.2%).	In	multivariate	analysis,	any	type	of	sepsis	was	associ-
ated	with	a	four-	fold	increase	in	the	odds	of	mortality	(aOR	3.90;	95%	
CI,	2.68–5.66);	however,	severe	sepsis	increased	the	odds	of	dying	20	
times	 (aOR	19.52;	95%	11.27–33.81)	 (Table	3).	Mortality	 in	women	
without	 sepsis	was	 early	 (median	 0.4	 days	 after	 delivery,	 interquar-
tile	range	0.2–0.8),	whereas	deaths	in	the	septic	group	were	delayed	
(median	4.0,	interquartile	range	0.7–7.9).
4  | DISCUSSION
In	 this	analysis	of	20	060	women	with	PPH,	 invasive	 treatments	 to	
manage	PPH	such	as	intrauterine	tamponade,	hysterectomy,	and	lapa-
rotomy	appear	to	increase	the	risk	of	sepsis.
Comparison	with	published	data	on	sepsis	 is	difficult	because	of	
differences	 in	 methods	 and	 definitions.	 However,	 the	 incidence	 of	
1.8%	 in	our	study	seems	high	compared	with	previous	figures.6,17,18 
This	 supports	 the	 hypothesis	 of	 an	 increased	 sepsis	 risk	 in	women	
with	PPH	and	 is	 in	 line	with	previous	studies.8,11,19	Explanations	for	
an	increased	risk	of	sepsis	include	an	observed	cesarean	delivery	rate	
of	29.1%,	which	is	higher	than	one	would	expect	based	on	published	
national	rates	for	cesarean	delivery.20	Cesarean	delivery	is	a	known	risk	
factor	for	both	PPH	and	sepsis.7,12	Moreover,	hemodynamic	instability	
is	a	result	of	PPH	and	causes	hypoperfusion,	which	impairs	the	natu-
ral	defense	mechanisms	of	the	body	against	 infection.	Nevertheless,	
after	controlling	for	these	and	other	possible	confounders,	 the	 inva-
sive	management	of	PPH	in	itself	appears	to	carry	an	infectious	risk.	
In	particular,	hysterectomy	(aOR	1.97),	 intrauterine	tamponade	(aOR	
1.77),	and	laparotomy	(aOR	6.63)	appear	to	increase	the	risk	of	sepsis.
As	consequences	of	sepsis	are	grave	(15%	mortality	for	any	type	
of	sepsis,	40%	in	those	with	severe	disease)	and	its	global	impact	big	
(11%	of	all	maternal	deaths	2	possibly	contributing	to	more	18),	preven-
tion	is	of	the	utmost	importance.	We	are	unable	to	evaluate	the	effect	
of	prophylactic	antibiotics	as	their	use	was	not	recorded.	Guidelines	
on	 PPH	 are	 heterogeneous	 in	 their	 recommendations	 on	 antibiot-
ics.12–14	However,	drawing	on	evidence	for	similar	interventions	such	
as	surgery	for	spontaneous	abortion,	cesarean	delivery,	and	hysterec-
tomy,7,21,22	antibiotic	prophylaxis	seems	likely	to	be	beneficial.
Hysterectomy	is	known	to	increase	the	risk	of	sepsis,	possibly	due	
to	opening	the	contaminated	vaginal	vault.22	The	high	risk	associated	
with	“laparotomy	for	other	reasons”	might	be,	at	least	partly,	explained	
by	reversed	causation	where	second-	look	laparotomies	and	washouts	
are	performed	for	women	with	an	intra-	abdominal	infection.	However,	
the	 protocol	 did	 aim	 to	 specifically	 record	 surgical	 interventions	 to	
treat	hemorrhage.	Women	with	PPH	who	undergo	surgery	might	be	
more	vulnerable	to	infection	than	women	who	have	elective	surgery,	
since	they	present	as	an	emergency	with	possible	additional	risk	fac-
tors	(e.g.	hemodynamic	instability,	nonhospital	delivery).
Concerns	about	infections	linked	to	intrauterine	tamponade	have	
been	 raised	 since	 the	 1950s,	 but	 the	 currently	 used	 balloon	 tam-
ponades	 are	 deemed	 safer	 in	 general	 than	 gauze	packing.	All	major	
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TABLE  1 Characteristics	of	the	study	population	and	univariate	analysis	of	risk	factors	for	sepsis	and	severe	sepsis	(n=20	018).
Characteristics No. of women Cases of sepsis (%) Crude OR (95% CI)a Cases of severe sepsis (%) Crude OR (95% CI)a
Type	of	delivery
Vaginal 14 189 193	(1.36) 1 63	(0.44) 1
Cesarean 5824 170	(2.91) 2.51	(2.00–3.16) 41	(0.70) 1.80	(1.17–2.77)
Missing 5 2 0
Age	group,	y
≤20 1978 31	(1.56) 1.10	(0.71–1.70) 8	(0.40) 1.47	(0.62–3.50)
20–25 4864 78	(1.60) 1 17	(0.35) 1
>25–30 6794 109	(1.60) 1.03	(0.76–1.39) 33	(0.49) 1.60	(0.88–2.94)
>30–40 6066 140	(2.30) 1.38	(1.03–1.85) 43	(0.71) 2.34	(1.30–4.22)
>40 309 7	(2.25) 1.52	(0.67–3.44) 3	(0.97) 3.32	(0.91–12.13
Missing 7 0 0
Hospital	delivery
Yes 17	587 294	(1.67) 1 82	(0.47) 1
No 2428 70	(2.88) 1.43	(1.07–1.92) 22	(0.91) 1.69	(1.02–2.86)
Unknown 3 1 0
Primary	cause	of	hemorrhage
Atony 12	759 165	(1.29) 1 50	(0.39) 1
Trauma 3681 88	(2.38) 1.60	(1.21–2.10) 22	(0.60) 1.17	(0.69–1.98)
Placenta	previa/accreta 1874 57	(3.04) 1.60	(1.15–2.22) 11	(0.59) 0.78	(0.39–1.56)
Other 1454 45	(3.09) 1.69	(1.19–2.41) 19	(1.31) 2.17	(1.23–3.88)
Unknown 250 10 2
Prophylactic	uterotonics
Yes 19	265 341	(1.77) 1 94	(0.49) 1
No 269 14	(5.19) 2.25	(1.25–4.06) 6	(2.23) 3.84	(1.56–9.42)
Unknown 484 10 4
Hemodynamic	instability
No 8194 66	(0.80) 1 12	(0.15) 1
Yes 11 823 299	(2.52) 3.17	(2.37–4.24) 92	(0.78) 6.39	(3.36–12.13)
Unknown 1 0 0
Estimated	blood	loss,	mL
≤1000 10 402 93	(0.89) 1 28	(0.27) 1
1001–2000 8284 206	(2.48) 3.01	(2.29–3.95) 50	(0.60) 3.20	(1.87–5.48)
>2000 1330 66	(4.94) 5.75	(4.02–8.21) 26	(1.95) 10.21	(5.39–19.35)
Unknown 2 0 0
Systolic	blood	pressure,	mm	Hg
≥100 12 097 156	(1.29) 1 31	(0.26) 1
90–99 4081 65	(1.59) 1.24	(0.92–1.70) 21	(0.51) 1.93	(1.08–3.45)
<90 3835 144	(3.74) 3.07	(2.39–3.94) 52	(1.36) 6.03	(3.72–9.79)
Unknown 5 0 0
Hysterectomy
No 18 997 293	(1.54) 1 79	(0.42) 1
Yes 1020 72	(7.06) 4.55	(3.41–6.07) 25	(2.45) 5.87	(3.56–9.66)
Unknown 1 0 0
(Continues)
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guidelines	recommend	the	use	of	intrauterine	tamponade	if	uteroton-
ics	are	ineffective	in	controlling	atony	12–14	and	considerable	enthusi-
asm	has	been	generated	since	a	2013	literature	review	concluded	that	
uterine	balloon	tamponade	was	an	effective	treatment	in	low-	resource	
settings.23	 However,	 from	 the	 13	 reviewed	 studies,	 six	 were	 case	
series	or	case	reports	and	none	had	a	comparison	group.	Uterotonics	
were	 used	 concomitantly	 and	 treatment	 success	 was	 observed	 in	
cases	with	balloon	volumes	of	only	30	mL,	making	it	hard	to	assess	the	
added	benefit	of	tamponade.	Only	241	women	were	included	in	total.	
A	larger	2016	systematic	review	including	1648	women	assessed	the	
evidence	for	intrauterine	tamponade	as	being	insufficient	owing	to	the	
small	numbers	of	study	participants	and	important	study	limitations.24 
While	there	were	few	reported	adverse	events,	the	review	notes	that	
harms	were	not	well	characterized.	However,	our	results	raise	the	pos-
sibility	that	tamponade	could	increase	the	risk	of	life-	threatening	sep-
sis.	This	calls	for	good-	quality	primary	research	into	the	benefits	and	
risks	of	tamponade	and	investigation	into	antibiotic	prophylaxis,	which	
is	not	currently	part	of	the	guidelines.
Of	course,	a	 lifesaving	 intervention	should	never	be	withheld	 to	
avoid	 the	 possible	 complication	 of	 sepsis,	 but	 clinicians	 should	 be	
aware	of	the	risk	and	the	importance	of	prevention,	early	recognition,	
and	correct	treatment.
To	our	knowledge,	the	present	study	is	the	first	to	look	at	possi-
ble	explanations	for	an	increased	infectious	risk	in	women	with	PPH.	
All	 recent	 publications	 that	 showed	 an	 association	 between	 sepsis	
and	PPH	were	from	studies	in	high-	income	countries	with	low	levels	
of	maternal	mortality	 8–11	 or	 only	 included	women	who	had	under-
gone	cesarean	delivery.19	The	WOMAN	 trial	 is	 a	 large	multicountry	
study	predominantly	 in	LMICs.	Recorded	variables	were	well-	chosen	
for	low-	resource	settings	and	data	collection	was	nearly	complete	for	
most	of	 them.	Severity	of	bleeding	 is	 likely	 to	be	an	 important	con-
founder	and	was	corrected	for	in	our	model	using	three	different	vari-
ables:	estimated	blood	loss,	systolic	blood	pressure,	and	hemodynamic	
instability.	Plausible	physiologic	mechanisms,	large	numbers	of	events,	
and	small	P	values	make	it	highly	unlikely	that	results	are	purely	due	to	
random	error.	Random	effects	were	included	in	the	model	to	account	
for	clustering	by	facility.
There	are	also	important	limitations	to	consider.	This	was	a	second-
ary	data	analysis	and	 the	original	 study	was	not	specifically	designed	
to	investigate	the	incidence	or	risk	factors	for	sepsis.	Clear	diagnostic	
criteria	were	provided	but	sepsis	was	a	secondary	outcome	collected	
from	patient	records.	It	was	only	measured	during	hospital	stay.	Longer	
admissions	 following	 surgical	 interventions	 for	 PPH	 provide	 more	
opportunity	for	sepsis	to	be	diagnosed,	and	the	effect	is	thus	potentially	
Characteristics No. of women Cases of sepsis (%) Crude OR (95% CI)a Cases of severe sepsis (%) Crude OR (95% CI)a
Manual	placenta	removal
No 18 138 302	(1.67) 1 89	(0.49) 1
Yes 1879 63	(3.35) 1.42	(1.05–1.93) 15	(0.80) 1.18	(0.66–2.12)
Unknown 1 1 0
Intrauterine	tamponade
No 18	583 310	(1.67) 1 73	(0.39) 1
Yes 1434 55	(3.84) 1.97	(1.38–2.82) 31	(2.13) 2.955	(1.74–5.02)
Unknown 1 1 0
Embolization
No 19 994 363	(1.82) 1 102	(0.51) 1
Yes 23 2	(8.7) 6.39	(1.23–33.35) 2	(8.7) 40.70	(7.00–236.52)
Unknown 1 1 0
Laparotomy
No 19 808 323	(1.63) 1 88	(0.44) 1
Yes 209 42	(20.1) 13.38	(8.98–19.93) 16	(7.66) 16.22	(8.66–30.32)
Unknown 1 1 0
Brace	sutures
No 19 467 339	(1.74) 1 91	(0.47) 1
Yes 550 26	(4.73) 2.67	(1.72–4.16) 13	(2.36) 4.35	(2.27–8.31)
Unknown 1 1 0
Artery	ligation
No 19	538 328	(1.68) 1 83	(0.42) 1
Yes 479 37	(7.72) 3.91	(2.63–5.82) 21	(4.38) 6.76	(3.85–11.87)
Unknown 1 1 0
aLogistic	regression	with	random	effects	to	account	for	clustering.
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overestimated.	Severe	sepsis	was	a	newly	created	variable	 from	sep-
sis	and	organ	dysfunction,	but	organ	dysfunction	could	also	have	been	
caused	by	hypoperfusion	rather	than	by	sepsis;	 therefore,	misclassifi-
cation	of	some	cases	 is	possible.	 In	effect,	the	analysis	of	risk	factors	
for	sepsis	is	a	cross-	sectional	survey,	as	information	on	both	exposure	
(management	of	PPH)	and	outcome	(sepsis)	were	recorded	at	the	same	
time	 (outcome	 form).	 Reversed	 causation	 is	 therefore	 a	 real	 danger.	
Sepsis	can	indeed	cause	bleeding,	through	a	cascade	of	organ	dysfunc-
tion	 leading	 to	 diffuse	 intravascular	 coagulation	 and	 abnormal	 clot-
ting,	and	hysterectomy	is	sometimes	performed	to	treat	sepsis	rather	
TABLE  2 Multivariate	analysis	of	risk	factors	for	sepsis,	corrected	for	clustering	using	random	effects	(n=19	752).
Risk factors
Sepsis Severe sepsis
aORa CI P valueb aORa CI P valueb
Hysterectomy 1.97 1.49–2.65 <0.001 1.97 0.83–2.46 0.033
Manual	placenta	removal 1.30 0.92–1.83 0.139 0.90 0.46–1.74 0.750
Intrauterine	tamponade 1.77 1.21–2.59 0.004 2.60 1.47–4.59 0.002
Laparotomy 6.63 4.29–10.24 <0.001 5.35 2.61–10.98 <0.001
Brace	sutures 1.09 0.66–1.81 0.7369 1.36 0.62–2.99 0.454
Artery	ligation 1.48 0.94–2.34 0.098 2.50 1.28–4.89 0.010
Age,	y 0.891 0.652
20–25	y 1 1
25–30	y 0.93 0.67–1.27 1.36 0.72–2.56
30–40 y 1.02 0.75–1.39 1.63 0.87–3.07
>40 0.76 0.30–1.91 1.37 0.32–5.79
≤20 1.09 0.69–1.73 1.40 0.56–3.46
Cesarean	delivery 1.99 1.49–2.65 <0.001 1.43 0.83–2.46 0.197
Estimated	blood	loss,	mL 0.006 0.139
≤1000 1 1
1001–2000 1.65 1.21–2.26 1.66 0.89–3.10
>2000 1.53 0.99–2.40 2.17 0.99–4.78
Systolic	blood	pressure,	mm	Hg <0.001 0.003
≥100 1 1
90–99 0.85 0.61–1.18 1.05 0.58–1.98
<90 1.57 1.17–2.13 2.36 1.32–4.19
Primary	cause	of	hemorrhage 0.016 0.002
Atony 1 1
Trauma 1.40 1.05–1.88 0.93 0.52–1.66
Placenta	previa/accreta 0.91 0.63–1.32 0.47 0.22–1.02
Other 1.54 1.06–2.23 2.37 1.31–4.29
Nonhospital	delivery 1.34 0.96–1.88 0.088 1.12 0.62–2.03 0.713
Signs	of	hemodynamic	
instability
1.76 1.25–2.47 0.001 2.60 1.24–5.43 0.008
Abbreviations:	aOR,	adjusted	odds	ratio;	CI,	confidence	interval.
aLogistic	regression	adjusting	for	all	variables	in	the	table	and	random	effects	to	correct	for	clustering	by	facility.
bBased	on	likelihood	ratio	testing.
TABLE  3 Effect	of	sepsis	on	mortality	after	adjusting	for	confounding.a
Deaths/no. (%) Odds ratio 95% CI P value
No	sepsis 428/19	653	(2.8) 1
Any	type	of	sepsis 55/365	(15.1) 3.90 2.68–5.66 <0.001
Nonsevere	sepsis 13/261	(5.0) 0.99 0.51–1.89
Severe	sepsis 42/104	(40.4) 19.52 11.27–33.81 <0.001
aAdjusted	for	age,	type	of	delivery,	signs	of	hemodynamic	instability,	hospital	delivery,	primary	cause	of	hemorrhage,	laparotomy,	intrauterine	tamponade,	
artery	ligation,	hysterectomy,	brace	sutures,	and	clustering.
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than	causing	 it.	 Indeed,	 for	11%	of	hysterectomies	 the	stated	 reason	
was	 “to	 remove	 a	 severely	 damaged,	 ruptured,	 or	 infected	 uterus.”	
Unfortunately,	we	were	unable	to	separate	out	the	hysterectomies	per-
formed	as	treatment	for	infection.	Furthermore,	“laparotomy	for	other	
reasons”	might	be	second-	look	laparotomies	for	abdominal	infections.	
The	original	study	did	not	collect	information	on	comorbidities	such	as	
(gestational)	diabetes	or	antibiotic	usage,	which	are	likely	to	be	effect	
modifiers,	although	unable	to	explain	the	associations	we	saw.
In	 conclusion,	 PPH	 and	 postpartum	 sepsis	 remain	 important	
causes	of	maternal	mortality	and	morbidity	worldwide.	 In	 this	 large	
multicountry	study,	women	who	received	certain	invasive	treatments	
to	manage	PPH	appeared	to	face	an	 increased	risk	of	sepsis,	which	
carried	a	high	case-	fatality	rate.	Primary	research	is	urgently	required	
to	 investigate	 this	 finding	 further	 and	 examine	ways	 to	 reduce	 the	
risk,	including	clearer	guidelines	on	the	use	of	prophylactic	antibiotics.	
In	 the	 interim,	 potential	 harms	 and	benefits	 of	 these	 interventions,	
particularly	 intrauterine	 tamponade,	 should	 be	 carefully	 weighed	
when	developing	policy	and	in	clinical	management	of	women.
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